Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics

H. Aizawa, T. Iwanaga, H. Inoue, S. Takata, K. Matsumoto, N. Takahashi, M. Yoshida, N. Hara

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Because eosinophilic airway inflammation is a characteristic feature of bronchial asthma, the treatment of airway inflammation is important in the management of asthma. Theophylline has been reported to reduce airway inflammation, in addition to its well-known bronchodilating effect. Objective: In order to evaluate the effects of theophylline on airway inflammation, we investigated 48 subjects with mild and moderate asthma. Methods: The patients were randomly divided into two groups, with or without theophylline treatment (control n = 24; theophylline, n = 24). We examined the level of serum eosinophil cationic protein (ECP), induced sputum samples, and peak expiratory flow (PEF) and obtained spirograms before and after 4 weeks of treatment with once-daily theophylline (200-600 mg/day) of subjects with mild or moderate asthma. Results: Theophylline significantly increased morning and evening PEF and significantly decreased the diurnal variation of PEF. After treatment with theophylline, both serum ECP and the percentage of eosinophils in induced sputum were significantly decreased. In contrast, peripheral blood eosinophil count was unchanged after treatment with theophylline. Conclusions: These findings suggest that theophylline reduces airway inflammation and the severity of asthma, presumably via suppression of both eosinophil activity and subsequent eosinophil infiltration of the airways. Copyright (C) 2000 S. Karger AG. Basel.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalInternational Archives of Allergy and Immunology
Volume121
Issue number2
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Eosinophil Cationic Protein
Theophylline
Sputum
Eosinophils
Asthma
Inflammation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics. / Aizawa, H.; Iwanaga, T.; Inoue, H.; Takata, S.; Matsumoto, K.; Takahashi, N.; Yoshida, M.; Hara, N.

In: International Archives of Allergy and Immunology, Vol. 121, No. 2, 01.01.2000, p. 123-128.

Research output: Contribution to journalArticle

Aizawa, H. ; Iwanaga, T. ; Inoue, H. ; Takata, S. ; Matsumoto, K. ; Takahashi, N. ; Yoshida, M. ; Hara, N. / Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics. In: International Archives of Allergy and Immunology. 2000 ; Vol. 121, No. 2. pp. 123-128.
@article{4c64680df636474283ff11f39704b3e6,
title = "Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics",
abstract = "Background: Because eosinophilic airway inflammation is a characteristic feature of bronchial asthma, the treatment of airway inflammation is important in the management of asthma. Theophylline has been reported to reduce airway inflammation, in addition to its well-known bronchodilating effect. Objective: In order to evaluate the effects of theophylline on airway inflammation, we investigated 48 subjects with mild and moderate asthma. Methods: The patients were randomly divided into two groups, with or without theophylline treatment (control n = 24; theophylline, n = 24). We examined the level of serum eosinophil cationic protein (ECP), induced sputum samples, and peak expiratory flow (PEF) and obtained spirograms before and after 4 weeks of treatment with once-daily theophylline (200-600 mg/day) of subjects with mild or moderate asthma. Results: Theophylline significantly increased morning and evening PEF and significantly decreased the diurnal variation of PEF. After treatment with theophylline, both serum ECP and the percentage of eosinophils in induced sputum were significantly decreased. In contrast, peripheral blood eosinophil count was unchanged after treatment with theophylline. Conclusions: These findings suggest that theophylline reduces airway inflammation and the severity of asthma, presumably via suppression of both eosinophil activity and subsequent eosinophil infiltration of the airways. Copyright (C) 2000 S. Karger AG. Basel.",
author = "H. Aizawa and T. Iwanaga and H. Inoue and S. Takata and K. Matsumoto and N. Takahashi and M. Yoshida and N. Hara",
year = "2000",
month = "1",
day = "1",
doi = "10.1159/000024307",
language = "English",
volume = "121",
pages = "123--128",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics

AU - Aizawa, H.

AU - Iwanaga, T.

AU - Inoue, H.

AU - Takata, S.

AU - Matsumoto, K.

AU - Takahashi, N.

AU - Yoshida, M.

AU - Hara, N.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Because eosinophilic airway inflammation is a characteristic feature of bronchial asthma, the treatment of airway inflammation is important in the management of asthma. Theophylline has been reported to reduce airway inflammation, in addition to its well-known bronchodilating effect. Objective: In order to evaluate the effects of theophylline on airway inflammation, we investigated 48 subjects with mild and moderate asthma. Methods: The patients were randomly divided into two groups, with or without theophylline treatment (control n = 24; theophylline, n = 24). We examined the level of serum eosinophil cationic protein (ECP), induced sputum samples, and peak expiratory flow (PEF) and obtained spirograms before and after 4 weeks of treatment with once-daily theophylline (200-600 mg/day) of subjects with mild or moderate asthma. Results: Theophylline significantly increased morning and evening PEF and significantly decreased the diurnal variation of PEF. After treatment with theophylline, both serum ECP and the percentage of eosinophils in induced sputum were significantly decreased. In contrast, peripheral blood eosinophil count was unchanged after treatment with theophylline. Conclusions: These findings suggest that theophylline reduces airway inflammation and the severity of asthma, presumably via suppression of both eosinophil activity and subsequent eosinophil infiltration of the airways. Copyright (C) 2000 S. Karger AG. Basel.

AB - Background: Because eosinophilic airway inflammation is a characteristic feature of bronchial asthma, the treatment of airway inflammation is important in the management of asthma. Theophylline has been reported to reduce airway inflammation, in addition to its well-known bronchodilating effect. Objective: In order to evaluate the effects of theophylline on airway inflammation, we investigated 48 subjects with mild and moderate asthma. Methods: The patients were randomly divided into two groups, with or without theophylline treatment (control n = 24; theophylline, n = 24). We examined the level of serum eosinophil cationic protein (ECP), induced sputum samples, and peak expiratory flow (PEF) and obtained spirograms before and after 4 weeks of treatment with once-daily theophylline (200-600 mg/day) of subjects with mild or moderate asthma. Results: Theophylline significantly increased morning and evening PEF and significantly decreased the diurnal variation of PEF. After treatment with theophylline, both serum ECP and the percentage of eosinophils in induced sputum were significantly decreased. In contrast, peripheral blood eosinophil count was unchanged after treatment with theophylline. Conclusions: These findings suggest that theophylline reduces airway inflammation and the severity of asthma, presumably via suppression of both eosinophil activity and subsequent eosinophil infiltration of the airways. Copyright (C) 2000 S. Karger AG. Basel.

UR - http://www.scopus.com/inward/record.url?scp=0034106915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034106915&partnerID=8YFLogxK

U2 - 10.1159/000024307

DO - 10.1159/000024307

M3 - Article

C2 - 10705222

AN - SCOPUS:0034106915

VL - 121

SP - 123

EP - 128

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2

ER -